<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/ms2024-009</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-8333</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЗАБОЛЕВАНИЯ БИЛИАРНОЙ СИСТЕМЫ И ПЕЧЕНИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>DISEASES OF THE BILIARY SYSTEM AND LIVER</subject></subj-group></article-categories><title-group><article-title>Роль короткоцепочечных жирных кислот в прогрессировании неалкогольной жировой болезни печени</article-title><trans-title-group xml:lang="en"><trans-title>The role of short-chain fatty acids in the progression of non-alcoholic fatty liver disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7452-7230</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кролевец</surname><given-names>Т. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Krolevets</surname><given-names>T. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кролевец Татьяна Сергеевна, к.м.н., доцент кафедры факультетской терапии и гастроэнтерологии, 644043, Омск, ул. Ленина, д. 12; </p><p>врач-гастроэнтеролог, 644024, Омск, ул. Лермонтова, д. 41</p></bio><bio xml:lang="en"><p>Tatyana S. Krolevets, Cand. Sci. (Med.), Associate Professor of the Department of Faculty Therapy and Gastroenterology, 12, Lenin St., Omsk, 644043;</p><p>Gastroenterologist, 41, Lermontov St., Omsk, 644024</p></bio><email xlink:type="simple">mts-8-90@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6581-7017</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ливзан</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Livzan</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ливзан Мария Анатольевна, чл.-корр. РАН, д.м.н., профессор, врач-гастроэнтеролог, главный внештатный терапевт по СФО, заведующий кафедрой факультетской терапии и гастроэнтерологии, ректор,</p><p>644043, Омск, ул. Ленина, д. 12</p></bio><bio xml:lang="en"><p>Maria A. Livzan, Corr. Member RAS, Dr. Sci. (Med.), Professor, Gastroenterologist, Chief Freelance Therapist in the Siberian Federal District, Head of the Department of Faculty Therapy and Gastroenterology, Rector,</p><p>12, Lenin St., Omsk, 644043</p></bio><email xlink:type="simple">mlivzan@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6300-367X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сыровенко</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Syrovenko</surname><given-names>M. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сыровенко Мария Ильинична, аспирант кафедры факультетской терапии и гастроэнтерологии, врач-гастроэнтеролог, 644043, Омск, ул. Ленина, д. 12; </p><p>644024, Омск, ул. Лермонтова, д. 41</p></bio><bio xml:lang="en"><p>Maria I. Syrovenko, Postgraduate Student of the Department of Faculty Therapy and Gastroenterology, 12, Lenin St., Omsk, 644043;</p><p>Gastroenterologist, 41, Lermontov St., Omsk, 644024</p></bio><email xlink:type="simple">mariapli@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Омский государственный медицинский университет; &#13;
Клинический кардиологический диспансер</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Omsk State Medical University;&#13;
Clinical Cardiology Dispensary</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Омский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Omsk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>06</day><month>06</month><year>2024</year></pub-date><volume>0</volume><issue>8</issue><fpage>50</fpage><lpage>58</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кролевец Т.С., Ливзан М.А., Сыровенко М.И., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Кролевец Т.С., Ливзан М.А., Сыровенко М.И.</copyright-holder><copyright-holder xml:lang="en">Krolevets T.S., Livzan M.A., Syrovenko M.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/8333">https://www.med-sovet.pro/jour/article/view/8333</self-uri><abstract><sec><title>Введение</title><p>Введение. В настоящее время признана многофакторная модель патогенеза неалкогольной жировой болезни печени (НАЖБП). Представляется интересным изучение вклада изменения состава микробиоты кишечника и ее метаболитов в развитии заболевания.</p></sec><sec><title>Цель</title><p>Цель. Оценить вклад исследования качественного состава кишечной микробиоты в отношении риска прогрессирования НАЖБП для снижения потерь здоровьесберегаю щего потенциала населения.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проведено открытое сравнительное исследование 83 пациентов зрелого возраста (56,6 года (46–63)), страдающ их НАЖБП. Исследовали уровень инсулина, лептина, его рецептора, адипонектина в сыворотке крови, зонулина в кале, определяли КЦЖК в кале. Анализ проводили в зависимости от фенотипов НАЖБП: степени стеатоза (1-я – 40 пациентов, 2-я – 18 и 3-я – 25), наличия НАСГ (n = 43), наличия фиброза (n = 35). Оценка степени стеатоза и фиброза проводилась с помощью эластометрии.</p></sec><sec><title>Результаты</title><p>Результаты. У пациентов с НАЖБП снижено абсолютное количество всех КЦЖК в кале. Анаэробный индекс отклонен в сторону резко отрицательных значений (-0,711 (-0,576-(-0,830)). Высокое относительное содержание пропионовой кислоты характерно для НАЖБП с фиброзом (p ≤ 0,05). Анаэробный индекс, относительное содержание изоС4 + изоС5 + изоС6 и масляной кислоты имело положительную связь с St-index (rs = 0,254, rs = 0,269, rs = 0,240, p ≤ 0,05). Увеличение относительного количества пропионовой кислоты связано с уменьшением FLI (rs= -0,229, p ≤ 0,05). Обнаружена положительная связь инсулина с абсолютным количеством масляной кислоты (rs = 0,228, p ≤ 0,05). Имелась обратная связь абсолютного и относительного количества изоС4 + изоС5 + изоС6 и Изо Cn/Cn с зонулином в кале (rs = -0,231, p ≤ 0,05, rs = -0,380, p ≤ 0,05 и rs = -0,332, p ≤ 0,05).</p></sec><sec><title>Заключение</title><p>Заключение. Для пациентов с НАЖБП характерно преобладание анаэробной флоры. Изменения содержания КЦЖК в кале может влиять на прогрессирование НАЖБП. Влияние КЦЖК на развитие и прогрессирование НАЖБП может быть опосредовано развитием инсулино- и лептинорезистентности, а также нарушением целостности кишечного барьера.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Nowadays, a multifactorial model of the pathogenesis of NAFLD is recognized. It is interesting to study the contribution of changes in the composition of the intestinal microbiota and its metabolites in the development of the disease.</p></sec><sec><title>Aim</title><p>Aim. To evaluate the contribution of research into the qualitative composition of the intestinal microbiota in relation to the risk of progression of NAFLD to reduce the loss of health- saving potential of the population.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. An open comparative study of 83 mature-aged patients (56.6 years (46–63)) suffering from NAFLD was conducted. The levels of insulin, leptin, its receptor, adiponectin in blood serum, zonulin in feces were studied, and SCFA in feces</p></sec><sec><title>was determined</title><p>was determined. The analysis was carried out depending on the phenotypes of NAFLD: the degree of steatosis (1 – 40 patients, degree 2 – 18 and degree 3 – 25), the presence of NASH (43 patients), the presence of fibrosis (fibrosis was found in 35 patients). The degree of steatosis and fibrosis was assessed using elastometry. The results of the study were analyzed using the Microsoft Excel, STATISTICA 12.0 software package.</p></sec><sec><title>Results</title><p>Results. In patients with NAFLD, the absolute number of all SCFA in the feces was reduced. The anaerobic index was deviated towards sharply negative values (-0,711 (-0,576-(-0,830)). A high level of propionic acid was noted among the patients with fibrosis (p &lt; 0.05). Anaerobic index, relative content of isoC4 + isoC5 + isoC6, relative content of butyric acid had a positive relationship with the St-index (rs = 0.254, rs = 0.269, rs = 0.240, p≤ 0.05). An increase in the relative amount of propionic acid was statistically significantly associated with a decrease of FLI (rs = -0.229, p ≤0.05). A positive correlation was found between the level of insulin and the absolute amount of butyric acid C4 (rs = 0.228, p ≤ 0.05). There was an inverse relationship of the absolute and relative amounts of isoC4+ isoC5 + isoC6 and Iso Cn/Cn with zonulin in the feces (rs = -0.231, p ≤ 0.05, rs = -0.380, p ≤ 0.05 and rs = -0.332, p ≤ 0.05, respectively).</p></sec><sec><title>Conclusion</title><p>Conclusion. There is the anaerobic flora among the patients with NAFLD. Modification of the content of SCFA in feces may affect to the progression of NAFLD. The effect of SCFA on the development and progression of NAFLD may be mediated by the development of insulin and leptin resistance, as well as an integrity violation of the intestinal barrier.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>фиброз печени</kwd><kwd>стеатогепатит</kwd><kwd>кишечный барьер</kwd><kwd>лептинорезистентность</kwd><kwd>гиперинсулинемия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>liver fibrosis</kwd><kwd>steatohepatitis</kwd><kwd>intestinal barrier</kwd><kwd>leptin resistance</kwd><kwd>hyperinsulinemia</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа подготовлена в рамках гранта Российского научного фонда № 22-75-00014 (соглашение №22-75- 00014 от 27 июля 2022 года), https://rscf.ru/project/22-75-00014.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809–2817.e28. https://doi.org/10.1016/j.cgh.2021.12.002.</mixed-citation><mixed-citation xml:lang="en">Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809–2817.e28. https://doi.org/10.1016/j.cgh.2021.12.002.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Евстифеева СЕ, Шальнова СА, Куценко ВА, Яровая ЕБ, Баланова ЮА, Имаева АЭ и др. Распространенность неалкогольной жировой болезни печени среди населения трудоспособного возраста: ассоциации с социально-демографическими показателями и поведенческими факторами риска (данные ЭССЕ-РФ-2). Кардиоваскулярная терапия и профилактика. 2022;21(9):3356. https://doi.org/10.15829/1728-8800-2022-3356.</mixed-citation><mixed-citation xml:lang="en">Evstifeeva SE, Shalnova SA, Kutsenko VA, Yarovaya EV, Balanova YuA, Imaeva AE et al. Prevalence of non-alcoholic fatty liver disease among the working-age population: associations with socio-demographic indicators and behavioral risk factors (ESSE RF-2 data). Cardiovascular Therapy and Prevention (Russian Federation). 2022;21(9):3356. (In Russ.) https://doi.org/10.15829/1728-8800-2022-3356.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин ВТ, Жаркова МС, Корочанская НВ, Хлынов ИБ, Успенский ЮП. Фенотипы неалкогольной жировой болезни печени в различных регионах Российской Федерации, диагностические и лечебные подходы в клинической практике. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2023;33(2):7–18. https://doi.org/10.22416/1382-4376-2023-33-2-7-18.</mixed-citation><mixed-citation xml:lang="en">Ivashkin VT, Zharkova MS, Korochanskaya NV, Khlynov IB, Uspensky YuP. Phenotypes of Non-Alcoholic Fatty Liver Disease in Different Regions of the Russian Federation, Diagnostic and Therapeutic Approach in Clinical Practice. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(2):7–18. (In Russ.) https://doi.org/10.22416/1382-4376-2023-33-2-7-18.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, Hanratty B. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of populationbased observational studies. PLoS Med. 2020;17(4):e1003100. https://doi.org/10.1371/journal.pmed.1003100.</mixed-citation><mixed-citation xml:lang="en">Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, Hanratty B. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of populationbased observational studies. PLoS Med. 2020;17(4):e1003100. https://doi.org/10.1371/journal.pmed.1003100.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23(47):8263–8276. https://doi.org/10.3748/wjg.v23.i47.8263.</mixed-citation><mixed-citation xml:lang="en">Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23(47):8263–8276. https://doi.org/10.3748/wjg.v23.i47.8263.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ливзан МА, Сыровенко МИ, Кролевец ТС. Неалкогольная жировая болезнь печени и риск злокачественных новообразований. Медицинский совет. 2023;17(18):75–82. https://doi.org/10.21518/ms2023-355.</mixed-citation><mixed-citation xml:lang="en">Livzan MA, Syrovenko MI, Krolevets TS. Non-alcoholic fatty liver disease and the risk of malignant tumors. Meditsinskiy Sovet. 2023;17(18):75–82. (In Russ.) https://doi.org/10.21518/ms2023-355.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Peleg N, Sneh Arbib O, Issachar A, Cohen-Naftaly M, Braun M, Shlomai A. Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease. PLoS ONE. 2018;13(8):e0202393. https://doi.org/10.1371/journal.pone.0202393.</mixed-citation><mixed-citation xml:lang="en">Peleg N, Sneh Arbib O, Issachar A, Cohen-Naftaly M, Braun M, Shlomai A. Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease. PLoS ONE. 2018;13(8):e0202393. https://doi.org/10.1371/journal.pone.0202393.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Маевская МВ, Котовская ЮВ, Ивашкин ВТ, Ткачева ОН, Трошина ЕА, Шестакова МВ и др. Национальный Консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями. Терапевтический архив. 2022;94(2):216–253. https://doi.org/10.26442/00403660.2022.02.201363.</mixed-citation><mixed-citation xml:lang="en">Maevskaya MV, Kotovskaya YuV, Ivashkin VT, Tkacheva ON, Troshina EA, Shestakova MV et al. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii Arkhiv. 2022;94(2):216–253. (In Russ.) https://doi.org/10.26442/00403660.2022.02.201363.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH et al. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. J Clin Med. 2020;9(8):2648. https://doi.org/10.3390/jcm9082648.</mixed-citation><mixed-citation xml:lang="en">Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH et al. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A NeverEnding Bidirectional Cross-Talk. J Clin Med. 2020;9(8):2648. https://doi.org/10.3390/jcm9082648.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Решетова МС, Зольникова ОЮ, Ивашкин ВТ, Ивашкин КВ, Апполонова СА, Лапина ТЛ. Роль кишечной микробиоты и ее метаболитов в патогенезе неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(5):75–88. https://doi.org/10.22416/1382-4376-2022-32-5-75-88.</mixed-citation><mixed-citation xml:lang="en">Reshetova MS, Zolnikova OYu, Ivashkin VT, Ivashkin KV, Appolonova SA, Lapina TL. Gut Microbiota and its Metabolites in Pathogenesis of NAFLD. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(5):75–88. (In Russ.) https://doi.org/10.22416/1382-4376-2022-32-5-75-88.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou D, Fan JG. Microbial metabolites in non-alcoholic fatty liver disease. World J Gastroenterol. 2019;25(17):2019–2028. https://doi.org/10.3748/wjg.v25.i17.2019.</mixed-citation><mixed-citation xml:lang="en">Zhou D, Fan JG. Microbial metabolites in non-alcoholic fatty liver disease. World J Gastroenterol. 2019;25(17):2019–2028. https://doi.org/10.3748/wjg. v25.i17.2019.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Лазебник ЛБ, Голованова ЕВ, Туркина СВ, Райхельсон КЛ, Оковитый СВ, Драпкина ОМ и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;1(1):4–52. https://doi.org/10.31146/1682-8658-ecg-185-1-4-52.</mixed-citation><mixed-citation xml:lang="en">Lazebnik LB, Golovanova EV, Turkina SV, Raikhelson KL, Okovityy SV, Drapkina OM et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4–52. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-185-1-4-52.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Бородкина ДА, Груздева ОВ, Акбашева ОЕ, Белик ЕВ, Паличева ЕИ, Барбараш ОЛ. Лептинорезистентность, нерешенные вопросы диагностики. Проблемы эндокринологии. 2018;64(1):62–66. https://doi.org/10.14341/probl8740.</mixed-citation><mixed-citation xml:lang="en">Borodkina DA, Gruzdeva OV, Akbasheva OE, Belik EV, Palicheva EI, Barbarash OL. Leptin resistance: unsolved diagnostic issues. Problemy Endokrinologii. 2018;64(1):62–66. (In Russ.) https://doi.org/10.14341/probl8740.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Бакулин ИГ, Сандлер ЮГ, Кейян ВА, Ротин ДЛ. Новый неинвазивный метод оценки стеатоза при хронических заболеваниях печени. Терапевтический архив. 2016;88(2):49–57. https://doi.org/10.17116/terarkh201688249-57.</mixed-citation><mixed-citation xml:lang="en">Bakulin IG, Sandler YuG, Keyan VA, Rotin DL. A new non-invasive method for assessing steatosis in chronic liver diseases. Terapevticheskii Arkhiv. 2016;88(2):49–57. (In Russ.) https://doi.org/10.17116/terarkh201688249-57.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ардатская МД, Бельмер СВ, Добрица ВП, Захаренко СМ, Лазебник ЛБ, Минушкин ОН и др. Дисбиоз (дисбактериоз) кишечника: современное состояние проблемы, комплексная диагностика и лечебная коррекция. Экспериментальная и клиническая гастроэнтерология. 2015;(5):13–50. Режим доступа: https://cyberleninka.ru/article/n/disbioz-disbakteriozkishechnika-sovremennoe-sostoyanie-problemy-kompleksnaya-diagnostikai-lechebnaya-korrektsiya.</mixed-citation><mixed-citation xml:lang="en">Ardatskaya MD, Bel’mer SV, Dobritsa VP, Zakharenko SM, Lazebnik LB, Minushkin ON et al. Colon dysbacteriosis (dysbiosis): modern state of the problem, comprehensive diagnosis and treatment correction. Experimental and Clinical Gastroenterology. 2015;(5):13–50. (In Russ.) Available at: https://cyberleninka.ru/article/n/disbioz-disbakterioz-kishechnikasovremennoe-sostoyanie-problemy-kompleksnaya-diagnostika-ilechebnaya-korrektsiya.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Tanes C, Bittinger K, Gao Y, Friedman ES, Nessel L, Paladhi UR et al. Role of dietary fiber in the recovery of the human gut microbiome and its metabolome. Cell Host Microbe. 2021;29(3):394–407.e5. https://doi.org/10.1016/j.chom.2020.12.012.</mixed-citation><mixed-citation xml:lang="en">Tanes C, Bittinger K, Gao Y, Friedman ES, Nessel L, Paladhi UR et al. Role of dietary fiber in the recovery of the human gut microbiome and its metabolome. Cell Host Microbe. 2021;29(3):394–407.e5. https://doi.org/10.1016/j.chom.2020.12.012.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ардатская МД, Гарушьян ГВ, Мойсак РП, Топчий ТБ. Роль короткоцепочечных жирных кислот в оценке состояния микробиоценоза кишечника и его коррекции у пациентов с НАЖБП различных стадий. Экспериментальная и клиническая гастроэнтерология. 2019;161(1):106–116. https://doi.org/10.31146/1682-8658-ecg-161-1-106-116.</mixed-citation><mixed-citation xml:lang="en">Ardatskaya MD, Garushyan GV, Moysak RP, Topchiy TB. Role of short chain fatty acids in evaluation of gut microbiocenosis disorders and their correction in patients with NAFLD of different stages. Experimental and Clinical Gastroenterology. 2019;161(1):106–116. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-161-1-106-116.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Chen J, Vitetta L. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. Int J Mol Sci. 2020;21(15):5214. https://doi.org/10.3390/ijms21155214.</mixed-citation><mixed-citation xml:lang="en">Chen J, Vitetta L. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. Int J Mol Sci. 2020;21(15):5214. https://doi.org/ 10.3390/ijms21155214.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F et al. The Severity of Nonalcoholic Fatty Liver Disease Is Associated With Gut Dysbiosis and Shift in the Metabolic Function of the Gut Microbiota. Hepatology. 2016;63(3):764–775. https://doi.org/10.1002/hep.28356.</mixed-citation><mixed-citation xml:lang="en">Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F et al. The Severity of Nonalcoholic Fatty Liver Disease Is Associated With Gut Dysbiosis and Shift in the Metabolic Function of the Gut Microbiota. Hepatology. 2016;63(3):764–775. https://doi.org/10.1002/hep.28356.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Schwimmer JB, Johnson JS, Angeles JE, Behling C, Belt PH, Borecki I et al. Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;157(4):1109–1122. https://doi.org/10.1053/j.gastro.2019.06.028.</mixed-citation><mixed-citation xml:lang="en">Schwimmer JB, Johnson JS, Angeles JE, Behling C, Belt PH, Borecki I et al. Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;157(4):1109–1122. https://doi.org/10.1053/j.gastro.2019.06.028.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Mouzaki M, Loomba R. Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention. Therap Adv Gastroenterol. 2019;12:1756284819858470. https://doi.org/10.1177/1756284819858470.</mixed-citation><mixed-citation xml:lang="en">Mouzaki M, Loomba R. Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention. Therap Adv Gastroenterol. 2019;12:1756284819858470. https://doi.org/10.1177/1756284819858470.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Lee G, You HJ, Bajaj JS, Joo SK, Yu J, Park S et al. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in nonobese NAFLD. Nat Commun. 2020;11(1):4982. https://doi.org/10.1038/s41467-020-18754-5.</mixed-citation><mixed-citation xml:lang="en">Lee G, You HJ, Bajaj JS, Joo SK, Yu J, Park S et al. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in nonobese NAFLD. Nat Commun. 2020;11(1):4982. https://doi.org/10.1038/s41467-020-18754-5.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Chen J, Zhao KN, Vitetta L. Effects of Intestinal Microbial-Elaborated Butyrate on Oncogenic Signaling Pathways. Nutrients. 2019;11(5):1026. https://doi.org/10.3390/nu11051026.</mixed-citation><mixed-citation xml:lang="en">Chen J, Zhao KN, Vitetta L. Effects of Intestinal Microbial-Elaborated Butyrate on Oncogenic Signaling Pathways. Nutrients. 2019;11(5):1026. https://doi.org/10.3390/nu11051026.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Chen J, Vitetta L. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. Int J Mol Sci. 2020;21(15):5214. https://doi.org/10.3390/ijms21155214.</mixed-citation><mixed-citation xml:lang="en">Chen J, Vitetta L. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. Int J Mol Sci. 2020;21(15):5214. https://doi.org/10.3390/ijms21155214.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Chen J, Vitetta L. The Role of Butyrate in Attenuating Pathobiont-Induced Hyperinflammation. Immune Netw. 2020;20(2):e15. https://doi.org/10.4110/in.2020.20.e15.</mixed-citation><mixed-citation xml:lang="en">Chen J, Vitetta L. The Role of Butyrate in Attenuating Pathobiont-Induced Hyperinflammation. Immune Netw. 2020;20(2):e15. https://doi.org/10.4110/in.2020.20.e15.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Schulthess J, Pandey S, Capitani M, Rue-Albrecht KC, Arnold I, Franchini F et al. The Short Chain Fatty Acid Butyrate Imprints an Antimicrobial Program in Macrophages. Immunity. 2019;50(2):432–445.e7. https://doi.org/10.1016/j.immuni.2018.12.018.</mixed-citation><mixed-citation xml:lang="en">Schulthess J, Pandey S, Capitani M, Rue-Albrecht KC, Arnold I, Franchini F et al. The Short Chain Fatty Acid Butyrate Imprints an Antimicrobial Program in Macrophages. Immunity. 2019;50(2):432–445.e7. https://doi.org/10.1016/j.immuni.2018.12.018.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Byndloss MX, Olsan EE, Rivera-Chávez F, Tiffany CR, Cevallos SA, Lokken KL et al. Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion. Science. 2017;357(6351):570–575. https://doi.org/10.1126/science.aam9949.</mixed-citation><mixed-citation xml:lang="en">Byndloss MX, Olsan EE, Rivera-Chávez F, Tiffany CR, Cevallos SA, Lokken KL et al. Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion. Science. 2017;357(6351):570–575. https://doi.org/10.1126/science.aam9949.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Fei N, Bruneau A, Zhang X, Wang R, Wang J, Rabot S et al. Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease. mBio. 2020;11(1):e03263-19. https://doi.org/10.1128/mBio.03263-19.</mixed-citation><mixed-citation xml:lang="en">Fei N, Bruneau A, Zhang X, Wang R, Wang J, Rabot S et al. Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease. mBio. 2020;11(1):e03263-19. https://doi.org/10.1128/mBio.03263-19.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Carpino G, Ben MD, Pastori D, Carnevale R, Baratta F, Overi D et al. Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. Hepatology. 2020;72(2):470–485. https://doi.org/10.1002/hep.31056.</mixed-citation><mixed-citation xml:lang="en">Carpino G, Ben MD, Pastori D, Carnevale R, Baratta F, Overi D et al. Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. Hepatology. 2020;72(2):470–485. https://doi.org/10.1002/hep.31056.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Liu L, Fu Q, Li T, Shao K, Zhu X, Cong Y et al. Gut microbiota and butyrate contribute to nonalcoholic fatty liver disease in premenopause due to estrogen deficiency. PLoS ONE. 2022;17(2):e0262855. https://doi.org/10.1371/journal.pone.0262855.</mixed-citation><mixed-citation xml:lang="en">Liu L, Fu Q, Li T, Shao K, Zhu X, Cong Y et al. Gut microbiota and butyrate contribute to nonalcoholic fatty liver disease in premenopause due to estrogen deficiency. PLoS ONE. 2022;17(2):e0262855. https://doi.org/10.1371/journal.pone.0262855.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou D, Pan Q, Xin FZ, Zhang RN, He CX, Chen GY et al. Sodium Butyrate Attenuates High-Fat Diet-Induced Steatohepatitis in Mice by Improving Gut Microbiota and Gastrointestinal Barrier. World J Gastroenterol. 2017;23(1):60–75. https://doi.org/10.3748/wjg.v23.i1.60.</mixed-citation><mixed-citation xml:lang="en">Zhou D, Pan Q, Xin FZ, Zhang RN, He CX, Chen GY et al. Sodium Butyrate Attenuates High-Fat Diet-Induced Steatohepatitis in Mice by Improving Gut Microbiota and Gastrointestinal Barrier. World J Gastroenterol. 2017;23(1):60–75. https://doi.org/10.3748/wjg.v23.i1.60.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Musso G, Gambino R, Cassader M. Obesity, diabetes, and gut microbiota: The hygiene hypothesis expanded? Diabetes Care. 2010;33(10):2277–2284. https://doi.org/10.2337/dc10-0556.</mixed-citation><mixed-citation xml:lang="en">Musso G, Gambino R, Cassader M. Obesity, diabetes, and gut microbiota: The hygiene hypothesis expanded? Diabetes Care. 2010;33(10):2277–2284. https://doi.org/10.2337/dc10-0556.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Vallianou N, Christodoulatos GS, Karampela I, Tsilingiris D, Magkos F, Stratigou T et al. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules. 2021;12(1):56. https://doi.org/10.3390/biom12010056.</mixed-citation><mixed-citation xml:lang="en">Vallianou N, Christodoulatos GS, Karampela I, Tsilingiris D, Magkos F, Stratigou T et al. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules. 2021;12(1):56. https://doi.org/10.3390/biom12010056.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou D, Chen YW, Zhao ZH, Yang RX, Xin FZ, Liu XL et al. Sodium Butyrate Reduces High-Fat Diet-Induced Non-Alcoholic Steatohepatitis Through Upregulation of Hepatic GLP-1R Expression. Exp Mol Med. 2018;50(12):1–12. https://doi.org/10.1038/s12276-018-0183-1.</mixed-citation><mixed-citation xml:lang="en">Zhou D, Chen YW, Zhao ZH, Yang RX, Xin FZ, Liu XL et al. Sodium Butyrate Reduces High-Fat Diet-Induced Non-Alcoholic Steatohepatitis Through Upregulation of Hepatic GLP-1R Expression. Exp Mol Med. 2018;50(12):1–12. https://doi.org/10.1038/s12276-018-0183-1.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao S, Jang C, Liu J, Uehara K, Gilbert M, Izzo L et al. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature. 2020;579(7800):586–591. https://doi.org/10.1038/s41586-020-2101-7.</mixed-citation><mixed-citation xml:lang="en">Zhao S, Jang C, Liu J, Uehara K, Gilbert M, Izzo L et al. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature. 2020;579(7800):586–591. https://doi.org/10.1038/s41586-020-2101-7.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Iannucci LF, Sun J, Singh BK, Zhou J, Kaddai VA, Lanni A et al. Short chain fatty acids induce UCP2-mediated autophagy in hepatic cells. Biochem Biophys Res Commun. 2016;480(3):461–467. https://doi.org/10.1016/j.bbrc.2016.10.072.</mixed-citation><mixed-citation xml:lang="en">Iannucci LF, Sun J, Singh BK, Zhou J, Kaddai VA, Lanni A et al. Short chain fatty acids induce UCP2-mediated autophagy in hepatic cells. Biochem Biophys Res Commun. 2016;480(3):461–467. https://doi.org/10.1016/j.bbrc.2016.10.072.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">den Besten G, Lange K, Havinga R, van Dijk TH, Gerding A, van Eunen K et al. Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids. Am J Physiol Gastrointest Liver Physiol. 2013;305(12):G900–G910. https://doi.org/10.1152/ajpgi.00265.2013.</mixed-citation><mixed-citation xml:lang="en">den Besten G, Lange K, Havinga R, van Dijk TH, Gerding A, van Eunen K et al. Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids. Am J Physiol Gastrointest Liver Physiol. 2013;305(12):G900–G910. https://doi.org/10.1152/ajpgi.00265.2013.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">den Besten G, Bleeker A, Gerding A, van Eunen K, Havinga R, van Dijk TH et al. Short-chain fatty acids protect against high-fat diet-induced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation. Diabetes. 2015;64(7):2398–2408. https://doi.org/10.2337/db14-1213.</mixed-citation><mixed-citation xml:lang="en">den Besten G, Bleeker A, Gerding A, van Eunen K, Havinga R, van Dijk TH et al. Short-chain fatty acids protect against high-fat diet-induced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation. Diabetes. 2015;64(7):2398–2408. https://doi.org/10.2337/db14-1213.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Lahham S, Roelofsen H, Rezaee F, Weening D, Hoek A, Vonk R et al. Propionic acid affects immune status and metabolism in adipose tissue from overweight subjects. Eur J Clin Invest. 2012;42(4):357–364. https://doi.org/10.1111/j.1365-2362.2011.02590.x.</mixed-citation><mixed-citation xml:lang="en">Al-Lahham S, Roelofsen H, Rezaee F, Weening D, Hoek A, Vonk R et al. Propionic acid affects immune status and metabolism in adipose tissue from overweight subjects. Eur J Clin Invest. 2012;42(4):357–364. https://doi.org/10.1111/j.1365-2362.2011.02590.x.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Takai A, Kikuchi K, Ichimura M, Tsuneyama K, Moritoki Y, Matsumoto K et al. Fructo-oligosaccharides ameliorate steatohepatitis, visceral adiposity, and associated chronic inflammation via increased production of short-chain fatty acids in a mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol. 2020;20(1):46. https://doi.org/10.1186/s12876-020-01194-2.</mixed-citation><mixed-citation xml:lang="en">Takai A, Kikuchi K, Ichimura M, Tsuneyama K, Moritoki Y, Matsumoto K et al. Fructo-oligosaccharides ameliorate steatohepatitis, visceral adiposity, and associated chronic inflammation via increased production of short-chain fatty acids in a mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol. 2020;20(1):46. https://doi.org/10.1186/s12876-020-01194-2.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Кролевец ТС, Ливзан МА, Сыровенко МИ. Фиброз печени при неалкогольной жировой болезни печени: роль адипокинов и неинвазивной оценки состояния кишечного барьера. Доказательная гастроэнтерология. 2023;12(2):46–54. https://doi.org/10.17116/dokgastro20231202146.</mixed-citation><mixed-citation xml:lang="en">Krolevets TS, Livzan MA, Syrovenko MI. Liver fibrosis in nonalcoholic fatty liver disease: the role of adipokines and noninvasive assessment of the intestinal barrier. Russian Journal of Evidence-Based Gastroenterology. 2023;12(2):46–54. (In Russ.) https://doi.org/10.17116/dokgastro 20231202146.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
